The changes in the brain signaling systems play an important role in etiology and
pathogenesis of Type 2 diabetes mellitus (T2DM) and metabolic syndrome (MS), being a …

Acromegaly is a rare disease due to chronic GH excess and to the consequent increase in
IGF-1 levels. Both GH and IGF-1 play a role in intermediate metabolism affecting glucose …

The management of hyperglycemia in patients with kidney failure is complex, and the goals
and methods regarding glycemic control in chronic kidney disease (CKD) are not clearly …

Purpose: Increased adrenergic activity in response to chronic stress is known to promote
tumor growth by stimulating the tumor microenvironment. The focus of the current study was …

The huge increase in type 2 diabetes is a burden worldwide. Many marketed compounds do
not address relevant aspects of the disease; they may already compensate for defects in …

While lifestyle modifications and metformin are the cornerstone of the initial management of
type 2 diabetes mellitus, there is an increasing array of second and third-line …

Background Prolactin is an anterior pituitary hormone that may modulate the adverse effects
of obesity. Prolactin has been associated with cardiovascular disease mortality, but less is …

Bromocriptine mesylate quick-release was approved by the Food and Drug Administration
(FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on …

Metformin is considered an initial drug of choice for type 2 diabetes mellitus by leading
recommendations. When contraindications to its use exist or patients cannot tolerate it due …

Dopamine action appears to play a role in changes that are seen in obesity, metabolic
syndrome and type 2 diabetes mellitus. Bromocriptine-QR (Quick Release), a dopamine …